Compare Bristol-Myers Squibb Co (BMY) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs FedEx Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.63 (market cap $116.30B), while FedEx Corporation trades at $315.56 (market cap $74.84B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | FDX | |
|---|---|---|
Market Cap | $116.30B | $74.84B |
Sector | Health | Industrials |
52-Week High | $62.37 | $338.75 |
52-Week Low | $42.60 | $174.81 |
Enterprise Value | $152.24B | $104.47B |
Dividend Yield | 4.42% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FedEx (FDX) trades at $313.74, down 0.3% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $6.31, beating expectations, and is executing strategic moves like the $1.4 billion sale of its supply chain unit to CMA CGM. Valuation ratios appear reasonable with a P/E of 16.91 and P/S of 0.79, while analyst consensus remains positive with a $358.80 price target.
The outlook is mixed; cost-cutting initiatives and debt reduction via a $4.15 billion tender offer support fundamentals, but weak shipping demand and margin pressures pose risks. Upside depends on margin recovery from DRIVE and Network 2.0 programs, though competitive threats from Amazon logistics and economic sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
